Effect of a statin on hepatic apolipoprotein B-100 secretion and plasma campesterol levels in the metabolic syndrome

International Journal of Obesity

Volumn 27, Issue 7, 2003, Pages 862-865

  Watts, G F ^a,b   Chan, D C ^a   Barrett, P H R ^a   O'Neill, F H ^c   Thompson, G R ^c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c NONE

Author keywords

ApoB metabolism; Cholesterol absorption; HMGCo A reductase inhibitors

Indexed keywords

APOLIPOPROTEIN B100; ATORVASTATIN; CAMPESTEROL; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LATHOSTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; STATINE DERIVATIVE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CHOLESTEROL SYNTHESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DYSLIPIDEMIA; GAS CHROMATOGRAPHY; HUMAN; INTESTINE ABSORPTION; LIPID ABSORPTION; LIPOPROTEIN METABOLISM; LIVER; MALE; MASS SPECTROMETRY; METABOLIC DISORDER; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL;

ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN B-100; APOLIPOPROTEINS B; CHOLESTEROL; CHOLESTEROL, VLDL; DOUBLE-BLIND METHOD; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PHYTOSTEROLS; PYRROLES;

EID: 0038342948     PISSN: 03070565     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijo.0802287     Document Type: Article

References (20)

1. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000; 106: 453-458.
2. Chan DC, Watts GF, Redgrave TG, Mori TA, Barrett PHR. Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration. Metabolism 2002; 51: 1041-1046.
3. Thompson GR, Naoumova R, Watts GF. Role of cholesterol in regulating apolipoprotein B secretion by the liver. J Lipid Res 1996; 37: 439-447.
4. Riches FM, Watts GF, Hua J, Stewart GR, Naoumova RP, Barrett PH. Reduction in visceral adipose tissue is associated with improvement in apolipoprotein B-100 metabolism in obese men. J Clin Endocrinol Metab 1999; 84:2854-2861.
5. Simonen PP, Gylling H, Howard AN, Miettinen TA. Introducing a new component of the metabolic syndrome: low cholesterol absorption. Am J Clin Nutr 2000; 72: 82-88.
6. Miettinen TA, Tilvis RS, Kesaniemi YA. Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. Am J Epidemiol 1990; 131: 20-31.
7. Gylling H, Miettinen TA. Effects of inhibiting cholesterol absorption and synthesis on cholesterol and lipoprotein metabolism in hypercholesterolemic non-insulin-dependent diabetic men. J Lipid Res 1996; 37: 1776-1785.
8. Simonen PP, Gylling H, Miettinen TA. Body weight modulates cholesterol metabolism in non-insulin dependent type 2 diabetics. Obes Res 2002; 10: 328-335.
9. Watts GF, Naoumova RP, Kelly JM, Riches FM, Croft KD, Thompson GR. Inhibition of cholesterogenesis decreases hepatic secretion of apoB-100 in normolipidemic subjects. Am J Physiol 1997; 273: 462-470.
10. Watts GF, Cummings MH, Umpleby M, Quiney JR, Naoumova R, Thompson GR. Sonksen PH. Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications. Eur J Clin Invest 1995; 25: 559-567.
11. Lindenthal B, Sudhop T, Schiedermaier P, Agnan M, Sauerbruch T, von Bergmann K. Serum plant sterols and biliary cholesterol secretion in humans: studies with ursodeoxycholic acid. J Lipid Res 2002; 43: 1072-1077.
12. Duane WC, Hunninghake DB, Freeman ML, Pooler PA, Schlasner LA, Gebhard RL. Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers cholesterol saturation index of gallbladder bile. Hepatology 1988; 8:1147-1150.
13. Vanhanen H, Kesäniemi YA, Miettinen TA. Pravastatin lowers serum cholesterol, cholesterol-precursor sterols, fecal steroids and cholesterol absorption in man. Metabolism 1992; 41: 588-595.
14. Duane WC. Effects of lovastatin and dietary cholesterol on sterol homeostasis in healthy human subjects. J Clin Invest 1993; 92: 911-918.
15. Sehayek E, Ono JG, Shefer S, Nguyen LB, Wang N, Batta AK, Salen G, Smith JD, Tall AR, Breslow JL. Biliary cholesterol excretion: a novel mechanism that regulates dietary cholesterol absorption. Proc Natl Acad Sci 1998; 95: 10194-10199.
16. Ostlund RE, Bosner MS, Stenson WF. Cholesterol absorption efficiency declines at moderate dietary doses in normal human subjects. J Lipid Res 1999; 40: 1453-1458.
17. Kesaniemi YA, Grundy SM. Overproduction of low density lipoproteins associated with coronary heart disease. Arteriosclerosis 1983; 3: 40-46.
18. Lamarche B, Tchernof A, Mauriege P, Cantin B, Dagenais GR, Lupien PJ, Despres JP. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998; 279: 1955-1961.
19. Bays HE, Moore PB, Drehobl MA, Rosenblatt S, Toth PD, Dujovne CA, Knopp RH, Lipka LJ, Lebeaut AP, Yang B, Mellars LE, Cuffie-Jackson C, Veltri EP, Ezetimibe Study Group. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther 2001; 23: 1209-1230.
20. Berge KE, von Bergmann K, Lutjohann D, Guerra R, Grundy SM, Hobbs HH, Cohen JC. Heritability of plasma noncholesterol sterols and relationship to DNA sequence polymorphism in ABCG5 and ABCG8. J Lipid Res 2002 43: 486-494.